Literature DB >> 6790148

Mycoplasmas in diseases of humans.

J E Embree, J A Embil.   

Abstract

The roles of Mycoplasma pneumoniae, M. hominis and Ureaplasma urealyticum in diseases of humans are currently under investigation. M. pneumoniae, which causes primary atypical pneumonia, is a well established pathogen of the respiratory tract. Complications of infection by this organism are also being recognized; they include disorders of the hematopoietic, cardiovascular, central nervous, musculoskeletal, cutaneous and gastrointestinal systems. The roles of the genital mycoplasmas M. hominis and U. urealyticum are controversial but may include infections of the genitourinary tract and in pregnancy as well as diseases of the newborn, such as neonatal pneumonia and meningitis. In this review atypical pneumonia due to M. pneumoniae is described and the role of mycoplasmas in other diseases is discussed.

Entities:  

Mesh:

Year:  1980        PMID: 6790148      PMCID: PMC1704661     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  61 in total

1.  COLD AGGLUTININS. I. OCCURRENCE OF COLD ISOHEMAGGLUTININS IN VARIOUS CONDITIONS.

Authors:  M Finland; O L Peterson; H E Allen; B A Samper; M W Barnes; M B Stone
Journal:  J Clin Invest       Date:  1945-07       Impact factor: 14.808

2.  Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis.

Authors:  R O Buscho; D Saxtan; P S Shultz; E Finch; M A Mufson
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

3.  Mycoplasma pneumoniae infection and arthritis in man.

Authors:  L A Hernandez; G E Urquhart; W C Dick
Journal:  Br Med J       Date:  1977-07-02

4.  The radiographic patterns of acute mycoplasma pneumonitis.

Authors:  D C Cameron; R N Borthwick; T Philp
Journal:  Clin Radiol       Date:  1977-03       Impact factor: 2.350

5.  Association of viral and mycoplasma infections with exacerbations of asthma.

Authors:  E Huhti; T Mokka; J Nikoskelainen; P Halonen
Journal:  Ann Allergy       Date:  1974-09

6.  Sexual activity and vaginal colonization with genital mycoplasmas.

Authors:  W M McCormack; P C Almeida; P E Bailey; E M Grady; Y H Lee
Journal:  JAMA       Date:  1972-09-18       Impact factor: 56.272

7.  Mycoplasma hominis and abortion.

Authors:  H J Harwick; R H Purcell; J B Iuppa; F R Fekety
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

8.  Birth weight and genital mycoplasmas in pregnancy.

Authors:  P Braun; Y H Lee; J O Klein; S M Marcy; T A Klein; D Charles; P Levy; E H Kass
Journal:  N Engl J Med       Date:  1971-01-28       Impact factor: 91.245

9.  Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance.

Authors:  H M Foy; G E Kenny; R McMahan; A M Mansy; J T Grayston
Journal:  JAMA       Date:  1970-11-30       Impact factor: 56.272

10.  Septic arthritis due to mycoplasma hominis. A case report and review of the literature.

Authors:  D G Verinder
Journal:  J Bone Joint Surg Br       Date:  1978-05
View more
  3 in total

1.  Growth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticum.

Authors:  K Nagata; E Takagi; H Satoh; H Okamura; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

2.  Epidemiology of genital infections caused by Mycoplasma hominis, M. genitalium and Ureaplasma urealyticum in Iran; a systematic review and meta-analysis study (2000-2019).

Authors:  Khadijeh Moridi; Mohammad Hemmaty; Amir Azimian; Mohammad Hosein Fallah; Hamid Khaneghahi Abyaneh; Kiarash Ghazvini
Journal:  BMC Public Health       Date:  2020-06-29       Impact factor: 3.295

3.  Far infrared radiation induces changes in gut microbiota and activates GPCRs in mice.

Authors:  Imran Khan; Sabrina Pathan; Xiao Ang Li; Wai Kit Leong; Wei Lin Liao; Vincent Wong; W L Wendy Hsiao
Journal:  J Adv Res       Date:  2019-12-23       Impact factor: 10.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.